Actively Recruiting
Investigating Safety of Sonrotoclax Dose Ramp-up with Zanubrutinib in Adults with Blood Cancers
Led by BeOne Medicines · Updated on 2026-10-26
258
Participants Needed
22
Research Sites
156 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety of new dosing schedules for sonrotoclax in adults with blood cancers, specifically chronic lymphocytic leukemia CLL and mantle cell lymphoma MCL. The study aims to find the best way to gradually increase the sonrotoclax dose to reduce risks such as tumor lysis syndrome TLS and related toxicities. This trial is a phase 12 open-label study supported by BeOne Medicines. Participants will start treatment with zanubrutinib alone, an approved drug that targets malignant B cells, followed by a combination of zanubrutinib and sonrotoclax. Sonrotoclax dosing will be increased gradually according to different schedules to reach the target daily dose. Treatment cycles last 28 days each, with 15 cycles for treatment-nave CLL patients and up to 27 cycles for relapsedrefractory MCL patients, who may continue zanubrutinib alone until disease progression or other criteria are met. During the study, participants will be monitored closely for safety, especially for signs of TLS and adverse events during approximately four months of dose ramp-up. Researchers will collect data on dose modifications and overall tolerability. The total participation time is about 17 months for treatment-nave CLL patients and up to 32 months for relapsedrefractory MCL patients, with ongoing assessments throughout the treatment period.
CONDITIONS
Brief Title
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
Research Team
S
Study Director
S
Study Director
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here